Clinical Trials Sponsored by Scint B.V.

Total 3572 results

NHS National Waiting Times Centre Board
Boston Scientific Corporation; Diagram B.V.; Venn Life Sciences; Cardialysis B.V.

Unknown

Xience Versus Synergy in Left Main PCI (IDEAL-LM)

Coronary Artery Disease
VieCuri Medical Centre
Siemens Healthineers Nederland B.V.

Recruiting

Improving the Accuracy of Referrals of Patients With Chest Pain (URGENT2)

Myocardial Infarction | Myocardial Ischemia | Chest Pain | Acute Coronary Syndrome | Heart Attack

Netherlands
Laboratoires Vivacy
Avania B.V.; Canfield Scientific Inc.

Active, not recruiting

Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face (MidFaceXXL)

Aging | Aesthetics | Volume Deficiency in the Mid-Face

France
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee (OAK)

Osteoarthritis of the Knee | Chronic Lower Back Pain

Belgium, Czechia, Germany, Hungary, Spain, United Kingdom
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Virus Diseases | Bacterial Infections
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Endometriosis

Belgium, Bulgaria, Germany, Hungary, Japan, Poland, Romania, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Virus Diseases | Bacterial Infections
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (ALBUM)

Type 2 Diabetes | Chronic Kidney Disease

Spain, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin (IMPRESSION)

Type 2 Diabetes Mellitus

Russian Federation
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Pharma Europe B.V.

Completed

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (MOBILE)

Neuropathic Pain | Post-Herpetic Neuralgia (PHN) | Painful Diabetic Peripheral Neuropathy (PDPN)

Czechia, Germany, Poland, United Kingdom
Astellas Pharma Europe B.V.

Terminated

A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy (BiGARD)

NSAID-induced Gastropathy

Russian Federation
Maastricht University Medical Center
KCI medical B.V

Completed

A Randomised Controlled Trial Comparing Vacuum Assisted Closure (V.A.C.®) With Modern Wound Dressings

Leg Ulcer

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP6294

United Kingdom
Astellas Pharma Europe B.V.

Completed

First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology

Healthy Volunteers

United Kingdom, Germany
Astellas Pharma Europe B.V.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

Healthy Subjects | Pharmacokinetics of ASP2205

United Kingdom
Astellas Pharma Europe B.V.

Completed

EC905 Pharmacokinetic Profile Study

Healthy | Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia | Phase 1

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects (MAD)

Healthy Volunteers | Pharmacokinetics of ASP7962

United Kingdom
Foundation for Liver Research
Janssen-Cilag B.V.

Completed

Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms (ETIM)

Chronic Hepatitis C

Netherlands
Astellas Pharma Europe B.V.

Terminated

To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis (DAISY)

Clostridium Difficile

France, Germany, Netherlands, Spain
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males

Pharmacokinetics of ASP8477 | Pharmacodynamics of ASP8477

France, Belgium
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Europe B.V.

Completed

A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans

Tolerability | Safety | Pharmacokinetics of ASP7962

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects

Healthy Subjects | Pharmacokinetics | DDI (Drug-Drug Interaction)

Germany
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)

Healthy Subjects | Pharmacokinetics | EC905 | Multiple Dose

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects

Healthy Subjects

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707

Pharmacokinetics of ASP1707

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics of ASP3652 | Pharmacodynamics of ASP3652

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Metabolic Processes

Netherlands
ANRS, Emerging Infectious Diseases
MCM Vaccines B.V.

Completed

Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients (VIHVAC-B)

HIV Infections

France
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects

Healthy Subjects | Drug-Drug Interaction (DDI)

United Kingdom
Astellas Pharma Europe B.V.

Completed

Absolute Bioavailability Study With Ipragliflozin

Healthy Subjects | Bioavailability of Ipragliflozin

United Kingdom
Pharming Technologies B.V.
University of Wisconsin, Madison

Withdrawn

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation

Kidney Transplantation | Graft Rejection

United States
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate FK778 in Kidney Transplant Patients

Kidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, Renal

Belgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
Medical University of Warsaw
Ausnutria Hyproca B.V.

Not yet recruiting

Effect Of a Goat Milk-Based Infant Formula On Gastrointestinal And Other Symptoms And Health-Related Quality Of Life.

Gastrointestinal Diseases | Infant Nutrition Disorders

Poland
University of Bath
Tired of Cancer B.V.

Recruiting

Engagement and Acceptability of the Untire mHealth App

Cancer-related Problem/Condition | Cancer-related Fatigue

United Kingdom
Radboud University Medical Center
Genzyme Europe B.V.

Recruiting

Cemiplimab for Secondary Angiosarcomas

Metastasis | Locally Advanced Sarcoma | Secondary Angiosarcoma

Netherlands
Diagram B.V.
Johnson & Johnson; Biosense Webster, Inc.

Recruiting

CFAE/Spatiotemporal Dispersion Guided Ablation Versus PVI Guided Ablation in Persistent AF (CIPA)

Chronic Atrial Fibrillation

France, Netherlands, Japan
Radboud University Medical Center
Quirem Medical B.V.

Completed

Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer (SLOTH-1)

Pancreas Cancer

Netherlands
Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
Astellas Pharma Europe B.V.

Completed

A Study of ASP8302 in Participants With Underactive Bladder

Underactive Bladder

Japan, Poland, Germany, Netherlands, Slovakia, United Kingdom
University Hospital, Basel, Switzerland
Pharming Technologies B.V.

Terminated

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Coronavirus Infections

Switzerland, Brazil, Mexico
Radboud University Medical Center
Quirem Medical B.V.

Completed

Real-time Imaging of Holmium Radioembolization: a Feasibility Study (Emeritus)

Liver Metastases | Liver Cancer

Netherlands
University of Wisconsin, Madison
Pharming Technologies B.V.

Unknown

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

Kidney Failure

United States

Clinical Trials Sponsored by Scint B.V.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations